Michael J Keating
#80,557
Most Influential Person Now
Researcher
Michael J Keating's AcademicInfluence.com Rankings
Download Badge
Physics
Michael J Keating's Degrees
- PhD Physics University of California, Berkeley
- Masters Physics Stanford University
Why Is Michael J Keating Influential?
(Suggest an Edit or Addition)Michael J Keating's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (2002) (5130)
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. (2008) (3147)
- National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. (1996) (1973)
- Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. (1997) (1203)
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. (2002) (1010)
- Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. (2005) (1000)
- ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. (2004) (973)
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011) (894)
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. (2020) (881)
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. (2018) (874)
- Superoxide dismutase as a target for the selective killing of cancer cells (2000) (818)
- Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. (1990) (807)
- Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. (2005) (791)
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. (2008) (714)
- Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. (1986) (692)
- Rituximab dose-escalation trial in chronic lymphocytic leukemia. (2001) (629)
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. (2012) (605)
- Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. (1987) (599)
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. (2011) (549)
- Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. (2004) (544)
- Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. (2005) (535)
- Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia (2004) (525)
- Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia (2006) (524)
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. (2016) (444)
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. (2008) (430)
- Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. (1985) (401)
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group (1988) (399)
- Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity (2004) (393)
- Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism (2006) (390)
- Inhibition of Mitochondrial Respiration (2003) (376)
- Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs (2015) (372)
- Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. (2002) (364)
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. (2016) (361)
- Clinical investigation of human alpha interferon in chronic myelogenous leukemia. (1987) (350)
- Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. (2007) (340)
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. (2014) (334)
- Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. (2009) (330)
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. (2010) (328)
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. (2008) (322)
- Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. (2003) (322)
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. (2003) (320)
- High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. (2007) (320)
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. (2015) (318)
- Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplantation Recipients: A Retrospective Study at a Major Cancer Center (2006) (308)
- Ibrutinib and Venetoclax for First-Line Treatment of CLL. (2019) (306)
- Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. (2010) (297)
- Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukemia (2012) (297)
- Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. (1996) (294)
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemia (1989) (294)
- Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. (1987) (293)
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition (2013) (291)
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. (2014) (288)
- Characteristics of accelerated disease in chronic myelogenous leukemia (1988) (285)
- Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. (2011) (280)
- Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. (2001) (279)
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. (2016) (277)
- Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol γ (2005) (271)
- Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. (1996) (271)
- Management of adverse events associated with idelalisib treatment: expert panel opinion (2015) (271)
- Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. (1986) (268)
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. (2009) (265)
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. (2009) (255)
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. (2003) (254)
- Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. (2005) (253)
- Richter's syndrome: a report on 39 patients. (1993) (250)
- Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. (2006) (247)
- K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis (2011) (247)
- Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth (2016) (243)
- Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia (2003) (242)
- Pregnancy among patients with chronic myeloid leukemia treated with imatinib. (2006) (231)
- Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. (2004) (230)
- Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. (2004) (228)
- Richter syndrome (2005) (228)
- Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. (1988) (228)
- Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia (2003) (228)
- Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis (2003) (226)
- Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. (2007) (225)
- microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. (2010) (224)
- Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. (1985) (221)
- A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. (2015) (220)
- Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. (2005) (218)
- Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. (2003) (217)
- Treatment of hairy cell leukemia with recombinant α-interferon (1986) (216)
- Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens (2015) (216)
- Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. (1990) (212)
- Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. (1992) (212)
- A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. (1992) (212)
- Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. (1990) (210)
- Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. (2006) (210)
- DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. (2001) (209)
- Acute promyelocytic leukemia. M.D. Anderson Hospital experience. (1986) (209)
- Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. (2008) (206)
- Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. (1999) (206)
- Metabolic Alterations in Highly Tumorigenic Glioblastoma Cells (2011) (205)
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. (2013) (201)
- STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. (2010) (201)
- Causes of initial remission induction failure in acute myelogenous leukemia. (1982) (199)
- L-asparaginase and PEG asparaginase--past, present, and future. (1993) (199)
- Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. (2012) (199)
- Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. (2003) (193)
- Treatment of systemic fungal infections with liposomal amphotericin B. (1989) (188)
- Primary refractory and relapsed adult acute lymphoblastic leukemia (1999) (186)
- Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. (2006) (184)
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. (2011) (184)
- Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. (2005) (183)
- Response to salvage therapy and survival after relapse in acute myelogenous leukemia. (1989) (179)
- Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia (2008) (179)
- The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. (2014) (178)
- Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. (1995) (177)
- Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. (1990) (174)
- Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. (1992) (174)
- Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. (1996) (174)
- Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. (1996) (172)
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. (2011) (171)
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia (2015) (170)
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. (2009) (169)
- Factors related to length of complete remission in adult acute leukemia (1980) (169)
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. (2008) (169)
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. (2009) (167)
- A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. (2004) (164)
- Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. (1987) (163)
- High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. (2003) (161)
- Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. (1987) (159)
- Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine Therapy (1987) (158)
- Rituximab in relapsed or refractory hairy cell leukemia. (2003) (157)
- The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia (2002) (156)
- Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. (2001) (156)
- Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes (2002) (156)
- Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. (2013) (152)
- Chronic myelogenous leukemia in nonlymphoid blastic phase (1999) (152)
- Infection and immunity in chronic lymphocytic leukemia. (2000) (151)
- Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. (2019) (150)
- Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. (2009) (148)
- Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. (2005) (147)
- Improved prospects for long-term survival in adults with acute myelogenous leukemia. (1982) (144)
- Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. (2008) (144)
- Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. (2003) (140)
- Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. (2014) (138)
- Characterization of 4 mantle cell lymphoma cell lines. (2003) (137)
- A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). (1985) (136)
- Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. (1998) (136)
- Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies (2004) (135)
- Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia (1997) (135)
- Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. (1999) (134)
- Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. (2004) (134)
- Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. (1986) (133)
- Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. (1988) (133)
- Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. (2002) (131)
- Hodgkin transformation of chronic lymphocytic leukemia (2006) (131)
- Phase II study of alemtuzumab in chronic lymphoproliferative disorders (2003) (130)
- Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. (2011) (129)
- Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival (2001) (128)
- Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. (1996) (127)
- Natural history of central nervous system acute leukemia in adults (1981) (126)
- Clinical pharmacology of polyethylene glycol-L-asparaginase. (1986) (126)
- Chronic lymphocytic leukemia in (Richter's) transformation. (1998) (125)
- Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. (2004) (125)
- Risk categories and refractory CLL in the era of chemoimmunotherapy. (2012) (125)
- Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. (2008) (125)
- RANDOMIZED TRIAL OF PROTECTED ENVIRONMENT — PROPHYLACTIC ANTIBIOTICS IN 145 ADULTS WITH ACUTE LEUKEMIA (1978) (125)
- Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes (2015) (125)
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. (2011) (124)
- Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy (2012) (123)
- A Randomized Comparative Trial of Three Aminoglycosides—Comparison of Continuous Infusions of Gentamicin, Aaikacin and Sisomicin Combined with Carbenicillin in the Treatment of Infections in Neutropenic Patients with Malignancies (1979) (122)
- Eradication of minimal residual disease in hairy cell leukemia. (2006) (121)
- Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia (2009) (120)
- Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone (2006) (119)
- Therapy-related leukemia and myelodysplastic syndrome. (1987) (118)
- Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). (1994) (116)
- Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. (1992) (116)
- Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. (2014) (116)
- Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. (1993) (116)
- Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact (2010) (114)
- Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. (2005) (114)
- Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. (1997) (114)
- Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. (2017) (113)
- Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. (1980) (113)
- Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase (2003) (113)
- Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers (2016) (113)
- Differences in CD33 intensity between various myeloid neoplasms. (2002) (111)
- Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. (2007) (111)
- A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia (1982) (110)
- Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. (2009) (109)
- A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. (1983) (109)
- Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. (1999) (109)
- Second cancer risk in hairy cell leukemia: analysis of 350 patients. (1997) (108)
- Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. (2009) (108)
- Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. (2002) (107)
- The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia (2006) (106)
- The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. (2002) (106)
- Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chroni (2003) (106)
- Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. (1982) (104)
- Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. (2006) (104)
- Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft‐versus‐host disease (1997) (103)
- Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. (1985) (103)
- Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study (2016) (103)
- Activity of alemtuzumab in patients with CD52‐positive acute leukemia (2006) (102)
- Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia (1993) (100)
- Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. (1993) (100)
- Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. (1987) (100)
- Thalidomide therapy for myelofibrosis with myeloid metaplasia (2006) (100)
- Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years (2008) (99)
- Systemic depletion of serum l-Cyst(e)ine with an engineered human enzyme induces production of reactive oxygen species and suppresses tumor growth in mice (2016) (99)
- Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. (1992) (99)
- Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. (2006) (99)
- Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib (2017) (98)
- Graft‐versus‐leukaemia effect after non‐myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP‐70 in refractory chronic lymphocytic leukaemia (2007) (97)
- Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia (2005) (97)
- Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome (2006) (97)
- Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. (2008) (95)
- Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells (2016) (95)
- Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. (1998) (95)
- Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. (1994) (95)
- Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. (2010) (95)
- Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. (2004) (95)
- Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors (2007) (94)
- Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. (1983) (94)
- Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. (2007) (94)
- Acute myeloblastic leukemia with hyperleukocytosis: Risk factors for early mortality in induction (1988) (93)
- Subacute pulmonary failure complicating therapy with high‐dose ara‐C in acute leukemia (1985) (93)
- Malignant gingival and skin "infiltrates" in adult leukemia. (1983) (93)
- Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia (2011) (92)
- 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. (1980) (92)
- High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. (2009) (92)
- Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. (2011) (91)
- The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. (2009) (91)
- Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. (2009) (91)
- Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. (2009) (90)
- Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. (1989) (90)
- OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. (2005) (89)
- Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway (2018) (88)
- Fludarabine therapy in macroglobulinemic lymphoma. (1990) (88)
- Therapy of acute myelogenous leukemia (1978) (88)
- The role of gemtuzumab ozogamicin in acute leukaemia therapy (2005) (88)
- The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells (2013) (88)
- Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. (2005) (87)
- Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. (2009) (87)
- Oral infections associated with chemotherapy in adults with acute leukemia. (1982) (86)
- Fatal pulmonary failure complicating high‐dose cytosine arabinoside therapy in acute leukemia (1990) (86)
- Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. (1995) (86)
- Effective Elimination of Cancer Stem Cells By a Novel Drug Combination Strategy (2013) (86)
- Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. (2013) (85)
- Epstein–Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms (2002) (85)
- The characteristics and outcome of patients with late relapse acute myelogenous leukemia. (1988) (85)
- Treatment of hairy cell leukemia with recombinant alpha-interferon. (1986) (84)
- The role of clofarabine in hematologic and solid malignancies—Development of a next‐generation nucleoside analog (2005) (84)
- The relevance of reticulin stain‐measured fibrosis at diagnosis in chronic myelogenous leukemia (1987) (84)
- Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). (2014) (84)
- Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (2007) (84)
- High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. (1986) (84)
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia (2017) (83)
- A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. (2007) (83)
- The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. (2003) (82)
- Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. (2003) (81)
- Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (2011) (80)
- Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. (2001) (79)
- Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia (2006) (79)
- Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia (2002) (79)
- Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes (2003) (79)
- Treatment of therapy-related leukemia and myelodysplastic syndrome. (1993) (79)
- Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. (2008) (79)
- A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. (2018) (78)
- Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count (1983) (78)
- Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia (2003) (78)
- Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. (1980) (78)
- Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome (2001) (77)
- Richter's transformation in chronic lymphocytic leukemia. (2006) (76)
- Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. (2008) (76)
- Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. (2017) (76)
- Stat3 Activates the Receptor Tyrosine Kinase Like Orphan Receptor-1 Gene in Chronic Lymphocytic Leukemia Cells (2010) (76)
- Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. (2010) (76)
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. (2013) (76)
- Chronic myelogenous leukaemia: haematological remissions with alpha interferon (1986) (76)
- A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens (2006) (75)
- Effects of low doses of recombinant human granulocyte‐macrophage colony stimulating factor (GM‐CSF) in patients with myelodysplastic syndromes (1991) (75)
- Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (75)
- Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies (2004) (75)
- MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis (2008) (74)
- Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. (1980) (73)
- Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia (2003) (73)
- Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients (2008) (73)
- Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. (1997) (73)
- Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen (1994) (71)
- Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray (2006) (71)
- p16INK4A and p15INK4B gene deletions in primary leukemias. (1995) (71)
- Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. (2013) (70)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2013) (70)
- Outcome of patients with acute myelogenous leukemia after second salvage therapy (2005) (70)
- The association of specific “favorable” cytogenetic abnormalities with secondary leukemia (1986) (70)
- Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. (1995) (69)
- Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. (1995) (69)
- Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. (2009) (69)
- Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP) (1981) (69)
- Combination therapy with methotrexate, vincristine, polyethylene‐glycol conjugated‐asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia (1999) (68)
- Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia (2002) (68)
- Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. (2006) (68)
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. (2014) (68)
- Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome (2002) (68)
- Growth dynamics in naturally progressing chronic lymphocytic leukaemia (2019) (67)
- Quantitative analysis of the oral complications of antileukemia chemotherapy. (1986) (67)
- Role of maintenance chemotherapy in acute promyelocytic leukemia (1987) (67)
- Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. (2000) (66)
- Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. (1992) (65)
- Phase II trial of mitoxantrone in refractory acute leukemia. (1983) (65)
- Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. (2009) (65)
- Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. (2006) (65)
- Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. (1989) (65)
- Treatment of fludarabine‐refractory chronic lymphocytic leukemia (2009) (64)
- Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. (2016) (64)
- Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion (2014) (63)
- Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. (2009) (63)
- Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (2001) (63)
- STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells (2011) (62)
- Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial (2016) (62)
- Establishment and characterization of a new mantle cell lymphoma cell line, Mino. (2002) (62)
- Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. (1996) (62)
- The importance of cytogenetic studies in adult acute lymphocytic leukemia. (1990) (62)
- Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients (1987) (61)
- Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells (2015) (61)
- Chemotherapy-induced oral mucositis in adult leukemia. (1981) (61)
- Clinical and prognostic features of philadelphia chromosome‐negative chronic myelogenous leukemia (1986) (61)
- The t(14;19)(q32;q13)‐positive small B‐cell leukaemia: a clinicopathologic and cytogenetic study of seven cases (2007) (61)
- Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls (2004) (60)
- Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (2012) (60)
- The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients (2012) (60)
- Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. (2011) (59)
- Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. (1992) (59)
- Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy (1977) (59)
- Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. (1987) (59)
- The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. (2000) (58)
- Phase II Study of Fludarabine, Cytarabine (Ara-C), Cyclophosphamide, Cisplatin and GM-CSF (FACPGM) in Patients With Richter's Syndrome or Refractory Lymphoproliferative Disorders (2002) (58)
- Phase I clinical investigation of homoharringtonine. (1984) (58)
- Fludarabine therapy in hairy cell leukemia (1991) (58)
- A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154 (2010) (57)
- AUTOLOGOUS BONE MARROW TRANSPLANTATION IN PATIENTS WITH ADULT ACUTE LEUKEMIA IN RELAPSE (1978) (57)
- Late relapses in acute myeloid leukemia: analysis of characteristics and outcome (2010) (57)
- Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. (1997) (57)
- A pilot study of interleukin‐2 for adult patients with acute myelogenous leukemia in first complete remission (1999) (57)
- Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. (1985) (57)
- In vitro effects of STI 571‐containing drug combinations on the growth of Philadelphia‐positive chronic myelogenous leukemia cells (2002) (56)
- Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial (2016) (56)
- The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease (2002) (56)
- Research methodology: Strengthening causal interpretations of nonexperimental data (2004) (56)
- Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. (1984) (56)
- Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. (1992) (56)
- Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. (1993) (56)
- Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. (1997) (56)
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation (2018) (55)
- Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. (2010) (54)
- Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells (2013) (54)
- Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. (1990) (54)
- Mitoxantrone and high‐dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia (1990) (54)
- Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. (2005) (54)
- Nutritional deficiencies in patients receiving cancer chemotherapy. (1990) (53)
- Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis (1995) (53)
- Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. (2004) (53)
- Intensive chemotherapy induction followed by interferon‐alpha maintenance in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia (1991) (53)
- Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia (1989) (53)
- Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. (1996) (53)
- Emerging information on the use of rituximab in chronic lymphocytic leukemia. (2002) (52)
- Novel immune-based treatment strategies for chronic lymphocytic leukemia. (2005) (52)
- A Randomized Study of Tobramycin Plus Ticarcillin, Tobramycin Plus Cephalothin and Ticarcillin, or Tobramycin Plus Mezlocillin in the Treatment of Infection in Neutropenic Patients with Malignancies (1984) (52)
- Biology and treatment of chronic lymphocytic leukemia. (2003) (52)
- Alemtuzumab: a novel monoclonal antibody (2001) (52)
- Pretreatment flow cytometry of DNA content in adult acute leukemia. (1980) (52)
- The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). (1979) (51)
- Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome (2009) (51)
- Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series (2006) (51)
- Mitoxantrone and high‐dose cytosine arabinoside in refractory acute myelogenous leukemia (1988) (51)
- Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease (2003) (51)
- Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. (2001) (50)
- Elimination of Chronic Lymphocytic Leukemia Cells in Stromal Microenvironment by Targeting CPT with an Anti-Angina Drug Perhexiline (2016) (50)
- Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. (1995) (50)
- CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma (2015) (50)
- Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. (1993) (50)
- Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. (1978) (50)
- Coagulation Abnormalities Induced by β-Lactam Antibiotics in Cancer Patients (1983) (49)
- 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. (1994) (49)
- Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. (2003) (49)
- Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. (2001) (49)
- Metabolism pathways in chronic lymphocytic leukemia (2016) (49)
- Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial (2014) (49)
- Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia (1988) (48)
- High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. (2000) (48)
- Infection prophylaxis in acute leukemia (1984) (48)
- Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia (2013) (48)
- Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. (1984) (48)
- The prognostic significance of p16INK4a/p14ARF locus deletion and MDM‐2 protein expression in adult acute myelogenous leukemia (2000) (48)
- Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. (1995) (48)
- GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia (1998) (47)
- High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. (2010) (47)
- Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial (2010) (46)
- Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. (2000) (46)
- Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence (2010) (46)
- Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. (2006) (46)
- The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients (2008) (45)
- Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia (2016) (45)
- Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high‐dose cytosine arabinoside (1988) (45)
- Sudden onset of the blastic phase of chronic myelogenous leukemia (2003) (45)
- Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. (1993) (45)
- Chronic lymphocytic leukemia in the young patient. (1998) (44)
- Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. (1994) (44)
- Allogeneic haematopoietic transplantation for Richter's syndrome (2000) (44)
- A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome (2003) (44)
- Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. (2002) (43)
- Intensive treatment of acute leukemia in adults 70 years of age and older (1987) (43)
- Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib (2016) (43)
- Phase I study of liposomal daunorubicin in patients with acute leukemia (1999) (43)
- Orofacial aspergillosis in acute leukemia. (1985) (43)
- Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients (2013) (42)
- Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. (2009) (42)
- Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. (1987) (41)
- Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. (2018) (41)
- Bone marrow cyclooxygenase‐2 levels are elevated in chronic‐phase chronic myeloid leukaemia and are associated with reduced survival (2002) (41)
- Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein: A clinicopathologic study of 26 cases (2005) (41)
- Yttrium‐90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome (2004) (40)
- Expression profile of MDM‐2 proteins in chronic lymphocytic leukemia and their clinical relevance (1997) (40)
- Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia (2003) (40)
- Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study (2006) (40)
- Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. (2005) (40)
- Case/control study of the role of splenectomy in chronic lymphocytic leukemia. (1997) (40)
- Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival☆ (2015) (40)
- A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. (1985) (39)
- The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. (2007) (39)
- Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. (2005) (39)
- Multiple‐dose granulocyte‐macrophage–colony‐stimulating factor plus 23‐valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia (2008) (39)
- Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia (2004) (39)
- Molecular heterogeneity in acute leukemia lineage switch. (1989) (39)
- Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL. (2006) (39)
- Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. (2003) (38)
- CD 38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia (2001) (38)
- T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. (2007) (38)
- Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia (2008) (38)
- 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma (1986) (38)
- A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. (1987) (38)
- Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. (1988) (38)
- Environmental exposures in cytogenetically defined subsets of acute nonlymphocytic leukemia. (1989) (38)
- Chemoimmunotherapy of chronic lymphocytic leukemia. (2007) (37)
- Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). (1981) (37)
- Molecular heterogeneity in acute leukemia lineage switch (1989) (37)
- Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial (2017) (37)
- Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. (2015) (36)
- Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells (2018) (36)
- STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells (2018) (36)
- Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) (2017) (35)
- Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia (2013) (35)
- Phase I trial of nelarabine in indolent leukemias. (2008) (35)
- Prediction of remission in adult acute leukemia. Development and testing of predictive models (1982) (35)
- Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. (2010) (35)
- CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. (2003) (35)
- Proteomic‐based prediction of clinical behavior in adult acute lymphoblastic leukemia (2006) (35)
- A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. (1991) (35)
- Richter transformation of CLL (2016) (35)
- Role of splenectomy in chronic lymphocytic leukemia. (1997) (34)
- High dose cyclophosphamide, BCNU, and VP‐16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia (1987) (34)
- Quantitative cytology in leukemia research. (1983) (34)
- Personalized medicine in CLL: current status and future perspectives. (2014) (33)
- LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. (2011) (33)
- Outcomes of patients with chronic lymphocytic leukemia treated with first‐line idelalisib plus rituximab after cessation of treatment for toxicity (2016) (33)
- Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high‐dose decadron (1987) (33)
- A phase 1 and 2 trial of rubidazone in patients with acute leukemia. (1977) (33)
- Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia (2003) (33)
- Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons (1988) (33)
- Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome. (2005) (33)
- Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia (2000) (33)
- Forodesine: review of preclinical and clinical data. (2010) (32)
- Chemoimmunotherapy of adult acute leukemia (1981) (32)
- Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. (2021) (32)
- Fludarabine phosphate therapy in other lymphoid malignancies. (1990) (32)
- Signal Transducer and Activator of Transcription–3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia (2013) (32)
- Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). (2009) (32)
- B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia (2017) (32)
- Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia (2003) (31)
- The evolving role of Alemtuzumab in management of patients with CLL (2005) (31)
- p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy (2009) (31)
- Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. (2015) (31)
- Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia (2012) (31)
- Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. (1997) (31)
- Toward the potential cure of leukemias in the next decade (2018) (31)
- Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. (1994) (31)
- Second malignancies in hairy cell leukemia (leukemic reticuloendotheliosis) (1982) (30)
- Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. (2011) (30)
- Mature T‐cell leukemias (2005) (30)
- Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. (2015) (30)
- Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses (2016) (30)
- Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. (2009) (30)
- Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia (2013) (30)
- Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. (2004) (30)
- Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. (1999) (30)
- Chemotherapy-associated oral hemorrhages in adults with acute leukemia. (1984) (29)
- UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. (2002) (29)
- T-cell prolymphocytic leukemia: a single-institution experience. (2005) (29)
- Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. (2007) (29)
- Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia (2016) (29)
- Targeting inflammatory pathways in chronic lymphocytic leukemia. (2013) (29)
- Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia (2019) (29)
- Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. (2007) (29)
- Granulocyte colony‐stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission (1993) (29)
- DNA aneuploidy in adult acute leukemia. (1987) (29)
- Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. (2009) (29)
- Orofacial fungal infections. Nine pathogens that may invade during chemotherapy. (1992) (29)
- Exposure histories in acute nonlymphocytic leukemia patients with a prior preleukemic condition (1991) (29)
- Hyperuricemic syndromes in cancer patients. (2005) (28)
- At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells (2016) (28)
- Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies (2018) (28)
- Host defence factors and prognosis in hairy cell leukemia. (1982) (28)
- Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy (2019) (28)
- Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients (2019) (28)
- FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). (2005) (28)
- Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia (1989) (28)
- A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression (2003) (28)
- Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. (1989) (28)
- Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. (2015) (28)
- Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B‐cell chronic lymphocytic leukemia (2003) (27)
- The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells12 (2017) (27)
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations (2018) (27)
- Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies (2002) (27)
- A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation (2018) (27)
- Clinical pharmacology of homoharringtonine. (1986) (27)
- Modulation of 9-β-d-Arabinofuranosyladenine 5′-Triphosphate and Deoxyadenosine Triphosphate in Leukemic Cells by 2′-Deoxycoformycin during Therapy with 9-β-d-Arabinofuranosyladenine (1982) (27)
- AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia (2020) (27)
- The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab (2018) (27)
- Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia (2002) (26)
- Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapy. (1983) (26)
- Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. (1999) (26)
- Downregulation of RARα in Mice by Antisense Transgene Leads to a Compensatory Increase in RARβ and RARγ and Development of Lymphoma (1997) (26)
- What is the Best Frontline Therapy for Patients with CLL and 17p Deletion? (2011) (26)
- The prognostic significance of bone marrow levels of neurofibromatosis‐1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome (2003) (26)
- Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. (1995) (26)
- Early Identification of Potentially Cured Patients with Acute Myelogenous Leukemia — A Recent Challenge (1982) (26)
- Biological and Clinical Heterogeneity of B-cell Chronic Lymphocytic Leukemia (2003) (26)
- Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells (1997) (26)
- Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. (2009) (26)
- Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients. (2007) (26)
- Clinical and Pharmacokinetic Study of Clofarabine in Chronic Lymphocytic Leukemia: Strategy for Treatment (2006) (25)
- Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients (1979) (25)
- Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. (2005) (25)
- Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. (1996) (25)
- Self‐administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia (2011) (25)
- Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine‐needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival (2008) (25)
- Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients (1984) (25)
- Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. (2007) (25)
- Predicting survival in chronic lymphocytic leukemia (2012) (25)
- Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. (1995) (25)
- Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. (1981) (24)
- Immunosuppression with purine analogues--the flip side of the gold coin. (1993) (24)
- Epstein‐Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia (2010) (24)
- The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide (2018) (24)
- Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics (2016) (24)
- Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL) (2008) (24)
- Ticarcillin plus clavulanic acid in the treatment of patients with cancer. (1985) (24)
- Association of a MicroRNA / TP 53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia (2010) (24)
- Fludarabine phosphate in lymphoma: an important new therapeutic agent. (1996) (23)
- Mitoxantrone and high‐dose etoposide for patients with relapsed or refractory acute leukemia (1991) (23)
- Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy (1985) (23)
- Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. (2015) (23)
- Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia (2016) (23)
- Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL) (2017) (23)
- Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL. (2004) (23)
- Chronic Lymphoproliferative Disorders: An Integrated Point of View for the Differential Diagnosis (2000) (23)
- Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. (2019) (23)
- A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). (2005) (23)
- Prognostic significance of CD 20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (2009) (23)
- Chemoimmunotherapy of chronic lymphocytic leukemia (2010) (23)
- Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor (2014) (23)
- Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. (2004) (23)
- Long‐term follow‐up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center (1997) (22)
- The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia (2013) (22)
- Pneumonia during remission induction chemotherapy in patients with AML or MDS. (1996) (22)
- Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. (2006) (22)
- Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia (2003) (22)
- Hairy cell leukemia: clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions. (1981) (22)
- Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. (2011) (22)
- Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis) (1980) (22)
- Nelarabine (2018) (22)
- Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. (1987) (22)
- In vivo cellular kinetic and pharmacological studies1–β–d– arabinofuranosylcytosine and 3–deazauridine chemotherapy for relapsing acute leukemia (1981) (22)
- A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (2011) (21)
- Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. (2007) (21)
- Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes. (2013) (21)
- Soluble syndecan‐1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia (2009) (21)
- Activation of the B‐cell receptor successively activates NF‐κB and STAT3 in chronic lymphocytic leukemia cells (2017) (21)
- Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. (2015) (21)
- Treatment of acute leukemia in protected environment units (1979) (21)
- Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. (1987) (21)
- Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) (2018) (21)
- Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression (2010) (21)
- Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. (2007) (21)
- Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. (1982) (21)
- Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000 (2018) (20)
- Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. (2014) (20)
- Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens (2014) (20)
- Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia. (2009) (20)
- A Randomized Trial of Valacyclovir Versus Valganciclovir To Prevent CMV Reactivation in Patients with CLL Receiving Alemtuzumab. (2005) (20)
- Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments (2019) (20)
- Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. (1987) (20)
- Bone involvement in hairy cell leukemia. (1983) (20)
- Complete hematologic and cytogenetic response to 2‐amino‐9‐β‐D‐arabinosyl‐6‐methoxy‐9H‐guanine in a patient with chronic myelogeneous leukemia in T‐cell blastic phase (1999) (20)
- Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? (2013) (20)
- A phase 2 study of yttrium‐90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia (2009) (20)
- Remission from central nervous system involvement in adults with acute leukemia effect of intensive therapy and prognostic factors (1985) (19)
- Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia. (1988) (19)
- CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. (2008) (19)
- Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. (2014) (19)
- Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. (1984) (19)
- Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. (2001) (19)
- Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism (2016) (19)
- Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways (2018) (19)
- Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia (2016) (19)
- Unusual mucocutaneous infections in immunosuppressed patients with leukemia--expansion of an earlier study. (1986) (19)
- Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL): The case for early intervention (2000) (19)
- Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR) (2010) (18)
- Central nervous system complications of a newly recognized subtype of leukemia (1987) (18)
- Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma. (1997) (18)
- The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy (2011) (18)
- Old Age: A Sign of Poor Prognosis in Patients With Chronic Myelogenous Leukemia (1987) (18)
- Molecular differences between small and large cells in patients with chronic lymphocytic leukemia (2003) (18)
- Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology (2004) (18)
- Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. (2004) (18)
- Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections (2017) (18)
- Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. (1999) (18)
- The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia (2012) (18)
- β2‐microglobulin normalization within 6 months of ibrutinib‐based treatment is associated with superior progression‐free survival in patients with chronic lymphocytic leukemia (2016) (18)
- Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses (2016) (18)
- Circulating CD 20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance (2003) (17)
- Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour (2006) (17)
- Differential Incorporation of AraC , Gemcitabine , and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells (1997) (17)
- Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review. (1994) (17)
- Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. (1985) (17)
- Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. (1985) (17)
- Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). (1997) (17)
- Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). (2009) (17)
- Combination therapy with ticarcillin and sulfamethoxazole-trimethoprim for infections in patients with cancer. (1981) (16)
- Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics (2016) (16)
- Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia? (2018) (16)
- Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma (2003) (16)
- Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia (2018) (16)
- 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. (1986) (16)
- Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia. (2005) (16)
- Infections in Patients With Chronic Lymphocytic Leukemia (2004) (16)
- Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex (2017) (16)
- Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte‐macrophage colony‐stimulating factor (1990) (16)
- Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia (2011) (16)
- Acute Leukemias VII (1998) (16)
- Rituximab in B‐cell disorders other than non‐Hodgkin's Iymphoma (2002) (16)
- Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. (2016) (16)
- The role of fludarabine in hematological malignancies. (1994) (16)
- Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy (2017) (16)
- DEFECTIVE NK CELL MECHANISM IN PATIENTS WITH LEUKEMIA1 (1985) (15)
- Comparison of results of salvage therapy in adult acute myelogenous leukemia. (1987) (15)
- Early intensification and short‐term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia (1986) (15)
- Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. (2013) (15)
- Gossypol , a BH 3 mimetic , induces apoptosis in chronic lymphocytic leukemia cells (2008) (15)
- Mechanisms of Cell Death of Chronic Lymphocytic Leukemia Lymphocytes by RNA-Directed Agent, 8-NH2-Adenosine (2005) (15)
- Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. (1987) (15)
- The significance of spliceosome mutations in chronic lymphocytic leukemia (2013) (15)
- Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. (2019) (15)
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53 (2019) (15)
- Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? (2006) (15)
- Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. (1984) (15)
- Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. (1981) (15)
- Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2011) (15)
- Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options (2010) (15)
- Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations (2021) (15)
- Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. (2010) (15)
- Premature chromosome condensation studies in human leukemia: 5. Prediction of early relapse. (1984) (15)
- Novel role of p 53 in maintaining mitochondrial genetic stability through interaction with DNA Pol c (2005) (15)
- Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities. (2007) (14)
- STAT3-Activated GM-CSFRα Translocates to the Nucleus and Protects CLL Cells from Apoptosis (2014) (14)
- Fine-needle aspiration biopsy findings in patients with small lymphocytic lymphoma transformed to hodgkin lymphoma. (2007) (14)
- Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2019) (14)
- Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). (2005) (14)
- Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219 (2009) (14)
- Characterization of the 13 q 14 Tumor Suppressor Locus in CLL : Identification of ALT 1 , an Alternative Splice Variant of the LEU 2 Gene 1 (2001) (14)
- Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2. (1987) (14)
- Inhibition of glycolysis in cancer cells (2005) (14)
- The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia (2004) (14)
- Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target, (2011) (14)
- Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes. (1988) (14)
- Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study (2014) (14)
- Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. (1993) (14)
- DNA-RNA measurements in patients with acute leukemia undergoing remission induction therapy. (1985) (14)
- Aurora-A kinase nuclear expression in chronic lymphocytic leukemia (2008) (14)
- Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). (2017) (14)
- Management of chronic lymphocytic leukemia: a changing field. (2002) (14)
- Application of the international scoring system for myelodysplasia to M.D. Anderson patients [3] (multiple letters) (1997) (14)
- B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia: A Report of Four Cases. (2015) (14)
- Results of Therapy with Interferon Alpha and Cyclic Combination Chemotherapy in Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Early Chronic Phase (2001) (14)
- STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage (2019) (14)
- High‐Dose Cyclophosphamide, BCNU, and Etoposide Followed by Autologous Bone Marrow Rescue as Treatment for Adult Acute Leukemia in Relapse (1986) (13)
- Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine (1996) (13)
- PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells (2019) (13)
- Richter’s transformation in chronic lymphocytic leukemia (2007) (13)
- Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results (2020) (13)
- A phase 2 study of idelalisib plus rituximab in treatment-na¨ ı ve older patients with chronic lymphocytic leukemia (2015) (13)
- Leukemia: A model for drug development. (1997) (13)
- Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant (2014) (13)
- Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia (2015) (13)
- A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia (2011) (13)
- Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia (2015) (13)
- ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2) (2016) (13)
- The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study (2016) (13)
- Is histological subtype a marker for environmental exposures in acute myelogenous leukemia? (1992) (13)
- The involvement of microRNA in the pathogenesis of Richter syndrome (2018) (13)
- Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (1997) (13)
- Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity (2015) (12)
- High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. (1993) (12)
- Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia (2014) (12)
- Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia. (1981) (12)
- Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapies (2007) (12)
- Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells (2016) (12)
- Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia--Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual Disease (2003) (12)
- Institute-Working Group (NCI-WG) 1996 guidelines Lymphocytic Leukemia (IWCLL) updating the National Cancer leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (12)
- Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial (2017) (12)
- Leukemia and cigarette smoking (1990) (12)
- Phase II trial of dihydroxyanthracenedione in acute leukemia (1982) (12)
- Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays. (2005) (12)
- Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence (2010) (12)
- CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma. (2013) (11)
- Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. (1983) (11)
- Phase I evaluation of intravenous difluoromethylornithine — a polyamine inhibitor (2004) (11)
- The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment (2019) (11)
- The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action (2021) (11)
- The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells (2011) (11)
- Effect of antileukemia chemotherapy on marrow, blood, and oral granulocyte counts. (1991) (11)
- Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies. (1988) (11)
- Use of a 4'-(9 acridinylamino) methanesulfon-m-anisidine (AMSA), cytosine-arabinoside (ara-C) vincristine prednisone combination (AMSA-OAP) in poor risk patients in acute leukemia (1981) (11)
- Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL. (2019) (11)
- Lenalidomide Induces Complete and Partial Responses in Patients with Relapsed and Treatment-Refractory Chronic Lymphocytic Leukemia (CLL). (2006) (11)
- Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma (2014) (11)
- Inhibition of fludarabine metabolism by arabinosylcytosine during therapy (2004) (11)
- Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. (1979) (11)
- Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators (2008) (10)
- TAD: a web interface and database for tissue microarrays. (2002) (10)
- Reversible bilateral lateral rectus muscle palsy associated with high‐dose cytosine arabinoside and mitoxantrone therapy (1986) (10)
- Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. (2020) (10)
- A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia. (2004) (10)
- Phase I Study of Taxol in Refractory Acute Myelogenous Leukemias Using a Weekly Schedule (1998) (10)
- Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implications. (1985) (10)
- Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia (2010) (10)
- Treatment of chronic lymphocytic leukemia. (2005) (10)
- Mucocutaneous granulocytic sarcomas of the head and neck. (1987) (10)
- Clinical studies with rubidazone. (1979) (10)
- Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia. (1993) (10)
- Emerging information on the use of rituximab in chronic lymphocytic leukemia. (2002) (10)
- Active specific immunization with allogeneic leukemia associated antigens or irradiated allogeneic leukemia cells in acute leukemia (1978) (10)
- In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. (1981) (10)
- Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. (1987) (10)
- CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia (2020) (10)
- Prospective randomized trial of antibiotic prophylaxis in acute leukemia. (1985) (9)
- Phase I--II study of 3-deazauridine in adults with acute leukemia. (1981) (9)
- Extended Follow-Up of a Chemo-Immunotherapy Regimen FCR (Fludarabine, F; Cyclophosphamide, C; and Rituximab, R) as Initial Therapy for Chronic Lymphocytic Leukemia (CLL). (2005) (9)
- Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). (2007) (9)
- Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. (2011) (9)
- SnapShot: chronic lymphocytic leukemia. (2014) (9)
- Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy (2017) (9)
- Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. (2011) (9)
- IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy. (2007) (9)
- The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. (2010) (9)
- Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR. (2008) (9)
- Microbial mucocutaneous infections in acute adult leukemia. Results of an 18-year inpatient study. (1986) (9)
- Factors Influencing Disease Free Interval after Achieving Complete Remission in Acute Leukemia (1984) (9)
- A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia (2018) (9)
- Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. (2021) (9)
- Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia (2015) (9)
- Cell kinetic analysis of interleukin-2 receptor-tested chronic lymphocytic leukemia using the AgNOR silver stain. (1994) (9)
- Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies (2015) (9)
- Long‐term follow‐up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T‐cell chimerism is associated with high relapse risk and inferior survival (2017) (9)
- Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53. (2016) (9)
- Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role? (1995) (9)
- A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. (2014) (9)
- Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells (2017) (8)
- PARATHYROID HORMONE RELATED PROTEIN IN HYPERCALCAEMIA IN CLL (1995) (8)
- Seventy percent of complete responders remain in continuous remission: Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL (2007) (8)
- Plasma as a source of mRNA for determining IgVH mutation status in patients with chronic lymphocytic leukaemia (2006) (8)
- Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). (1993) (8)
- Monoclonal antibody combinations in CLL: evolving strategies. (2006) (8)
- Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy (1981) (8)
- Signal Transducer and Activator of Transcription (Stat)-3 Activates the Receptor Tyrosine Kinase-Like Orphan (ROR)-1 Gene in Chronic Lymphocytic Leukemia (CLL). (2009) (8)
- Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia (2017) (8)
- Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. (1996) (8)
- CD79b Expression in Chronic Lymphocytic Leukemia (2009) (8)
- Del(20q) in patients with chronic lymphocytic leukemia: A therapy-related abnormality involving lymphoid or myeloid cells (2015) (8)
- Refractory Chronic Lymphocytic Leukemia (2004) (8)
- Phase I Study of Continuous-Infusion Nelarabine in Patients with Advanced Lymphoid Malignancies (2011) (8)
- Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). (2007) (8)
- Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) (2007) (8)
- Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1] (2019) (8)
- The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL). (2006) (8)
- Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic (2016) (8)
- Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia (2017) (8)
- Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. (2019) (8)
- Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis. (2007) (8)
- Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study (2015) (8)
- High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome (2015) (8)
- Prognostic factors for survival of 194 patients with low infiltrate leukemia. (1986) (8)
- Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). (2005) (8)
- Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation (2021) (7)
- Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). (2019) (7)
- STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells (2018) (7)
- A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL ≤ 70 years (yrs). (2006) (7)
- Pregnancy in a patient with hypereosinophilic syndrome. (2009) (7)
- Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy (2009) (7)
- The Immunophenotype Signature CD49d+CD38+ Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells. (2009) (7)
- Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). (2009) (7)
- Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib (2016) (7)
- Evolution of oligoleukemia (1984) (7)
- FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia (2014) (7)
- T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia--evidence for lymphoid lineage prematurity. (1987) (7)
- Hematologic malignancies and pregnancy (1994) (7)
- Chronic lymphocytic leukemia presenting in association with aplastic anemia (2002) (7)
- Effect of Combined Treatment with 4-Hydroperoxycyclophosphamide and Fludarabine on Cytotoxicity and Repair of Damaged DNA (1998) (7)
- Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab (2016) (7)
- Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. (2014) (7)
- An Observational Study of the Occurrence of Atrial Fibrillation and Hypertension in Patients Treated with Ibrutinib (2014) (7)
- Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia (2008) (7)
- Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). (2009) (7)
- Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC (2012) (7)
- Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo. (2010) (7)
- Mucocutaneous herpetic infections during cancer chemotherapy. (1988) (6)
- Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells (2018) (6)
- Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Sub (2016) (6)
- Oral Idarubicin in Haematological Malignancies (1995) (6)
- Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia (2022) (6)
- In vitro effects of STI571-containing drug combinations on growth of Ph-posittve myelogenous leukemia-derived cells (2000) (6)
- Pharmacologically directed design of leukemia therapy. (1990) (6)
- Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. (2008) (6)
- Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms (2007) (6)
- Is Chronic Lymphocytic Leukemia Still Incurable (2012) (6)
- Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons. (1988) (6)
- The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience (2015) (6)
- Proteasome Inhibitors Induce Apoptosis in Glucocorticoid-Resistant Chronic (6)
- Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center. (2008) (6)
- Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). (2012) (6)
- The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL (2020) (6)
- Human malignancy-associated nucleolar antigen as a marker for tumor cells in patients with acute leukemia (1984) (6)
- Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis (2013) (6)
- Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA) (1984) (6)
- ZAP-70 Status May Not Predict Outcome after Non-Myeloablative Allogeneic Transplantation (NMT) in Patients with Chronic Lymphocytic Leukemia(CLL) Who Failed Conventional Chemotherapy. (2005) (6)
- Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. (2010) (6)
- Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia (2010) (6)
- Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia. (1989) (5)
- A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. (2022) (5)
- Prognostic markers in chronic lymphocytic leukemia (2012) (5)
- Conventional Management of Chronic Lymphocytic Leukemia (2000) (5)
- A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia (2015) (5)
- Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL. (2005) (5)
- Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. (1988) (5)
- Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS) (2010) (5)
- Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment response. (1982) (5)
- Role of splenectomy in chronic lymphocytic leukemia11Presented at the 48th Annual Cancer Symposium of the Society of Surgical Oncology, Boston, MA, March 21–24, 1995. (1997) (5)
- Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience (2020) (5)
- Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy (2017) (5)
- In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial (2012) (5)
- Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence? (2013) (5)
- Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkitt’s and Burkitt’s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL). (2005) (5)
- Richter's syndrome – update on biology and management (2014) (5)
- A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL (2016) (5)
- Prognostic factors in hairy cell leukemia. (Leukemic reticuloendotheliosis) (1984) (5)
- Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia (2017) (5)
- Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL. (2004) (5)
- Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia. (2006) (5)
- A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia (2016) (5)
- Group 1996 guidelines Working - Lymphocytic Leukemia updating the National Cancer Institute leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (5)
- Remission induction therapy with a rubidazone containing combination (ROAP) in acute leukemia (1977) (5)
- Apoptosis in chronic lymphocytic leukemia (1994) (5)
- External expressions of internal malignancy. (1987) (5)
- Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL. (2006) (5)
- Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study (2020) (5)
- The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures. (2011) (5)
- Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. (1993) (5)
- Clinical Experience with Fludarabine in Leukaemia (2012) (5)
- Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL) (2008) (4)
- TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis (2022) (4)
- Occupational exposure to silica and cancer risk (2004) (4)
- Management of Chronic Myeloid Leukemia (CML) during Pregnancy Among Patients (pts) Treated with a Tyrosine Kinase Inhibitor (TKI): A Single-Center Experience (2017) (4)
- Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL). (2019) (4)
- Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine. (1982) (4)
- Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB in Chronic Lymphocytic Leukemia Cells (2011) (4)
- Long-term chemotherapy-induced remission in a probable case of hairy cell leukemia. (1981) (4)
- Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia (2017) (4)
- Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). (2010) (4)
- Monoclonal antibodies in chronic lymphocytic leukemia (2006) (4)
- Shifting paradigms in the treatment of chronic lymphocytic leukemia. (2015) (4)
- Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. (2016) (4)
- Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells (2022) (4)
- Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia. (2008) (4)
- Oral Idarubicin in Patients with Late Chronic Phase Chronic Myelogenous Leukemia or Chronic Myelomonocytic Leukemia (2000) (4)
- CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells (2019) (4)
- Clinical and pharmacologic studies with rubidazone (R) in adults with acute leukemia (AL) (1976) (4)
- DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells (2014) (4)
- Biologic and Treatment Determinants of Curability in Acute Myelogenous Leukemia (1986) (4)
- Necrotizing dermatitis in patients receiving cancer chemotherapy. (1987) (4)
- Multifaceted actions of 8-amino-adenosine kill BCR–ABL positive cells (2012) (4)
- A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. (2010) (4)
- Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation (2018) (4)
- A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia (2013) (4)
- Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia (2003) (4)
- The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients (2008) (4)
- Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. (2007) (4)
- Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study. (2006) (4)
- The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's Transformation and FLU-refractory CLL. (2006) (4)
- Adhesion of B-Cell Chronic Lymphocytic Leukemia Cells to Marrow Stromal Cells is Mediated by α4β1 but not β2αL Integrin: MSC also Prevent Apoptosis of B-CLL Cells (2001) (4)
- Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry (2011) (4)
- Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). (2009) (4)
- Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. (2014) (4)
- In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemia. (1984) (4)
- Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance (2014) (4)
- A method for evaluation of novel therapy in previously untreated patients: AMSA-OAP combination therapy in adult acute leukemia (1982) (4)
- Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL) (2014) (4)
- Acute leukemia in adults, 1977 (1977) (4)
- Outcome of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation (2013) (4)
- Comparison of results of salvage therapy in acute leukemia (1982) (4)
- A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL, (2011) (3)
- Membrane-Stable, Humanized CD154 Gene Therapy for Patients with CLL. (2006) (3)
- Comparative Efficacy of First Line Therapies for Chronic Lymphocytic Leukemia: a Systematic Review and Meta-Analyses. (2009) (3)
- Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. (2012) (3)
- Array CGH Analysis of Chronic Lymphocytic Leukemia Reveals Frequent Cryptic Monoallelic and Biallelic Deletions of Chromosome 22q11. (2008) (3)
- Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells (2019) (3)
- CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia. (2004) (3)
- Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL). (2012) (3)
- A phase two study of high dose blinatumomab in Richter’s syndrome (2022) (3)
- Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature. (2006) (3)
- Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy (2012) (3)
- Fludarabine in the treatment of lymphoproliferative malignancies. (1993) (3)
- Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL) (2012) (3)
- Cellular pharmacology of arabinosylcytosine 5'-triphosphate (araCTP) in leukemic cells during high-dose araC therapy (1982) (3)
- Human malignancy-associated nucleolar antigen as a marker for tumor cells in patients with acute leukemia. (1984) (3)
- Current guidelines in defining therapeutic strategies. (2004) (3)
- patients with chronic lymphocytic leukemia inducer of apoptosis than bortezomib in lymphocytes from The proteasome inhibitor NPI-0052 is a more effective Updated (2006) (3)
- Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence. (1996) (3)
- Infection prophylaxis during remission induction therapy of acute leukemia (1981) (3)
- Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy (2011) (3)
- Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. (2019) (3)
- STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells (2021) (3)
- Combination Therapy with Alemtuzumab and Pentostatin Is Effective and Has Acceptable Toxicity in Patients with T-Lymphoid Neoplasms. (2006) (3)
- All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL). (2007) (3)
- Protected environments and microbial suppression in cancer therapy. (1977) (3)
- Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leukemia (APL). (2006) (3)
- Salvage therapy following failure or relapse after FCR chemo-immunotherapy as initial treatment for chronic lymphocytic leukemia (CLL) (2007) (3)
- Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. (2011) (3)
- Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB In Chronic Lymphocytic Leukemia (CLL) Cells (2010) (3)
- Effect of Recombinant Tumor Necrosis Factor a in vitro and Its Modulation by a and y Interferons (2005) (3)
- Acute Leukemias V (1996) (3)
- Long-term results of fi rst salvage treatment in CLL patients treated initially with FCR ( fl udarabine , cyclophosphamide , rituximab ) (2014) (3)
- and Treatment of Chronic Lymphocytic Leukemia (2003) (3)
- Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL). (2012) (3)
- Short-term sequential (S-TS) chemotherapy in young patients with acute myelogenous leukemia (AML) (1981) (3)
- Early Ofatumumab Treatment For High-Risk, Treatment-Naive Patients With Chronic Lymphocytic Leukemia (2013) (2)
- PHASE I TRIAL OF ANTI-B4 BLOCKED RICIN (B4bR) GIVEN AS A 28 DAY CONTINUOUS INFUSION (CI) (1994) (2)
- RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia (2015) (2)
- Phase I-II study of aziridinylbenzoquinone in acute leukemia (1982) (2)
- Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia (2014) (2)
- Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease (2021) (2)
- Points from Letters: Synthetic Drugs and Carcinoma (1964) (2)
- Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia (2013) (2)
- Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors (1990) (2)
- Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort (2008) (2)
- Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience (2016) (2)
- Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic study. (1987) (2)
- Treatment of adult acute myeloblastic leukemia. (1979) (2)
- Fundamentals of Platelet and Granulocyte Support in Myelosuppressed Leukemia and Bone Marrow Transplant Patients (1984) (2)
- Preclinical and early clinical study of forodesine hydrochloride (FH) in chronic lymphocytic leukemia (CLL). (2006) (2)
- Conclusions regarding leukemia long‐term survival (1997) (2)
- Treatment Effect of First Line Rituximab, Fludarabine and Cyclosphosphamide in a Chronic Lymphocytic Leukemia Patient Cohort: An Evaluation of Prognostic Factors, Estimated Life Expectancy and Economic Outcomes (2008) (2)
- Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF. (1990) (2)
- Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. (2009) (2)
- Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation. (2005) (2)
- Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia (2012) (2)
- Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia (2021) (2)
- Leukemia, whither goest thou? (1994) (2)
- Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia (2010) (2)
- Immune anemias in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy. (2006) (2)
- 2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies (1991) (2)
- Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia (2015) (2)
- Paraproteins in CLL Are Frequently the Product of Another Clone. (2004) (2)
- Infections in Patients with Chronic Lymphocytic Leukemia Treated with Chemoimmunotherapy. (2005) (2)
- Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. (2005) (2)
- The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration, (2011) (2)
- The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide (2015) (2)
- Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia (2013) (2)
- High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) or RAEB in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy (1994) (2)
- Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL. (2012) (2)
- Pharmacologically directed chemotherapy: A rational approach toward antitumor drug utilization (1985) (2)
- Deletion 11q Abnormality in Patients With Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (Clinical and Radiological) at Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients With CLL and del11q Cytogenetic Abnormality (2013) (2)
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients (2013) (2)
- Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). (2010) (2)
- Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results (2021) (2)
- Pharmacologically Guided Leukemia Therapy (1992) (2)
- Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia. (1987) (2)
- Second Cancers after CLL Diagnosis. (2004) (2)
- AML in the Elderly (2001) (2)
- The efficacy of non-myeloablative allogeneic stem cell transplantation in ZAP-70 positive/chemo-antibody refractory patients with chronic lymphocytic leukemia (CLL) (2005) (2)
- The Effect of Initial Therapy Choice in Determining Long Term Survival in Patients with Chronic Lymphocytic Leukemia (CLL). (2006) (2)
- Superficial head and neck metastases in adults with widespread cancer. (1980) (2)
- Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant (2015) (2)
- High Blast Percentage, Chromosome 17 Abnormalities and Severe Pancytopenia Predict Death within Twelve Months in Patients with Myelofibrosis. (2007) (2)
- STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells (2022) (2)
- Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy. (2012) (2)
- Gram-negative bacillary infections in cancer patients. (1977) (2)
- Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia(CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias. (2008) (2)
- Chemotherapy of Chronic Lymphocytic Leukemia (2004) (2)
- Abstract 3325: Role of smac-mimetic in restoring apoptosis in chronic lymphocytic leukemia . (2013) (2)
- Leukemia-associated skin infiltrates. (1989) (2)
- Plasma Circulating Ki-67 Index as a Biomarker and Prognostic Indicator in Patients with Chronic Lymphocytic Leukemia. (2009) (2)
- Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p (2008) (2)
- The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype (2019) (2)
- Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing (2019) (2)
- Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation (2014) (2)
- Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile (2014) (2)
- DNA cross-linking and repair in Cisplatin-resistant human tumor-cells following exposure to a new Cisplatin analog, ci-973. (1994) (2)
- High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. (1982) (2)
- Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. (2018) (2)
- Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes (2016) (1)
- Clinical Staging and Other Prognostic Features (2003) (1)
- Marrow Stromal Cells Induce TCL1 Expression in Chronic Lymphocytic Leukemia B Cells. (2009) (1)
- Abstract 3073: Targeting chronic lymphocytic leukemia by interfering glutathione synthesis using a novel therapeutic enzyme cyst(e)inase (AEB3103) (2016) (1)
- Hematological Malignancies (2004) (1)
- CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment. (2009) (1)
- Diagnostic Techniques in Hematological Malignancies: Mature B-cell leukemias (2010) (1)
- Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-Line FCR (2018) (1)
- A phase I/II study of Xcellerated T Cells in patients with chronic lymphocytic leukemia (2005) (1)
- Evaluation of T Cell Compartment By Mass Cytometry Reveals Distinct Patterns of Expression of Exhaustion Markers in Chronic Lymphocytic Leukemia (2017) (1)
- Surface Antigens Identified by Antibody Microarray That Correlate with IgVH Mutational Status and ZAP70 Expression in CLL. (2005) (1)
- Marcia Ogasawara , Michael and high dependency on glycolysis Metabolic alterations in highly tumorigenic glioblastoma cells : preference for hypoxia (2011) (1)
- The eosinophilic variant of acute myelomonocytic leukemia developing as a secondary leukemia in a patient with mycosis fungoides. (1987) (1)
- The Clinical Usefulness of Novel Prognostic Factors in CLL: A Study of 477 Patients with Low-Risk (Non-11q, Non-17p) FISH and Known IGVH Mutation Status. (2007) (1)
- Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) (2021) (1)
- Fludarabine treatment of chronic lymphocytic leukemia and indolent lymphomas (1990) (1)
- Variations in Proteasome Enzymatic Activities in Plasma of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and Their Value in Predicting Clinical Behavior. (2006) (1)
- Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia (2010) (1)
- Abstract 3528: Quantitation of ATM function in primary CLL cells. (2013) (1)
- Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior. (2005) (1)
- Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007 (2007) (1)
- Models predictive for survival in untreated patients with CLL at initial presentation and initial treatment (2005) (1)
- Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy (2015) (1)
- PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia (2012) (1)
- 5.59 Lenalidomide Induces Long-lasting Responses in Elderly Patients with Chronic Lymphocytic Leukemia (2011) (1)
- Epidermal Growth Factor Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia. (2006) (1)
- Genomics STAT 3-Activated GM-CSFR a Translocates to the Nucleus and Protects CLL Cells from Apoptosis (2014) (1)
- Chemoimmunotherapy for Patients with Chronic Lymphocytic Leukemia: MD Anderson Experience Beyond FCR300 (2016) (1)
- Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion, (2011) (1)
- Chronic lymphoproliferative disorders: chronic lymphocytic leukemia and hairy‐cell leukemia (1993) (1)
- Abstract 3547: B cell receptor signaling regulates cellular metabolism in Chronic Lymphocytic Leukemia (2017) (1)
- Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia. (2005) (1)
- Therapeutic approaches to chronic lymphocytic leukemia. (1991) (1)
- A Prognostic Score for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Analysis of 2189 Patients. (2006) (1)
- Pre-treatment characteristics predictive of complete remission in patients with relapsed acute leukemia treated with AMSA (1982) (1)
- Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL) (2010) (1)
- Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients. (2006) (1)
- Increased Expression of CD152 by Normal T Lymphocytes in Untreated Patients with B Cell Chronic Lymphocytic Leukemia. (2004) (1)
- High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL). (2008) (1)
- Defining response criteria in CLL patients treated in clinical research trials Response (2010) (1)
- Mitoxantrone in the Treatment of Acute Leukemias (1992) (1)
- PROGNOSIS OF ACUTE LEUKÆMIA IN ADULTS* (1974) (1)
- New Approaches in the Treatment of AML and MDS (1996) (1)
- untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously (2013) (1)
- N-BLR, a primate-specific non-coding transcript, modulates the epithelial-to-mesenchymal transition and leads to colorectal cancer invasion and migration (2014) (1)
- Advances in aminoglycoside antibiotic therapy (1976) (1)
- Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo (2016) (1)
- Therapy of oligoleukemia and pre-leukemia with methanol extraction residue of BCG (MER) and lithium carbonate (LC) (1981) (1)
- Symptom profiles in patients with chronic lymphocytic leukemia: validation and application of the M. D. Anderson Symptom Inventory (2010) (1)
- Clinical Significance of Free Circulating CD33 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. (2006) (1)
- Prognostic Significance of Beta-2 Microglobulin (B2M) in Adult Acute Lymphoblastic Leukemia (ALL). (2009) (1)
- Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al (2009) (1)
- Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL). (2010) (1)
- Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data (2022) (1)
- The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells. (2007) (1)
- Respiratory Defect and Hypoxia Overcome Drug Resistance Associated with Mitochondrial Inhibition of Glycolysis in Cancer Cells : A Novel Strategy to Updated (2005) (1)
- Mass Cytometry Reveals Heterogeneity in the Exhaustion Profile of T-Cells in Chronic Lymphocytic Leukemia and the CD4:CD8 Ratio May be a Reliable Predictor of CD8+ T Cell Compartment Fitness (2016) (1)
- STAT3 Activates Anti-Apoptotic Genes But When In Access Induces Apoptosis Of CLL Cells (2013) (1)
- Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC) (2011) (1)
- Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) (2014) (1)
- Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia (2011) (1)
- Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies. (2011) (1)
- IL-2 receptor expression and ki-67 flow cytometric analysis in B-chronic lymphocytic-leukemia. (1995) (1)
- Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA in Small lymphocytic lymphoma/Chronic lymphocytic leukemia (CLL) (2013) (1)
- In vivo cell cycle effects of 4 9 acridinylamino methanesulfon m anisidide in relapsing adult acute leukemia (1980) (1)
- Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders. (2005) (1)
- Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells (2017) (1)
- Knowledge acquisition from historical data: application to breast cancer patients. (1980) (1)
- Variations in Proteasome Enzymatic Activities in Plasma of Patients with Chronic Lymphocytic Leukemia and Their Value in Predicting Clinical Behavior. (2006) (1)
- High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia (2015) (1)
- Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease. (2008) (1)
- Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. (2015) (1)
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First‐Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p: Abstract: CLL‐018 (2017) (1)
- Fludarabine and Ara-C Combination for Treatment of Adult Acute Myelogenous Leukemia: Pharmacokinetic and Pharmacodynamic Effects (1996) (1)
- Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administration (1988) (1)
- “T-Cell-Rich B-Cell Lymphoproliferative Disorder” of the Bone Marrow (2001) (1)
- Abstract 4091: Epigenetic silencing of microRNA in the pathobiology of CLL (2010) (1)
- IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment (2015) (1)
- Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience (2016) (1)
- Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL). (2005) (1)
- 5-bromodeoxyuridine (BUdR) quenching of acridine orange fluorescence distinguishes cycling and non-cycling normal and malignant bone marrow cells in vitro. (1989) (1)
- Abstract LB-106: A novel TCL1-Tg:p53−/− mouse model of human CLL (2012) (1)
- Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. (2007) (1)
- Biologic agents for the management of hematological disorders: chronic myeloid leukemia. (1987) (1)
- Abstract 343: Targeting SF3B1 mediated splicing control of Mcl-1 in chronic lymphocytic leukemia (2014) (1)
- Measurement and Clinical Relevance of Proteasome Enzymatic Activity in Plasma of Patients with Acute Lymphoblastic Leukemia. (2006) (1)
- Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience (2016) (1)
- A Phase I/II trial of CD3/CD28 activated T cells in patients with chronic lymphocytic leukemia (CLL). (2004) (1)
- Pathogenesis and etiology (2019) (1)
- Long Term Follow-Up of Patients with Hairy Cell Leukemia (HCL). (2004) (1)
- Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells (2015) (1)
- Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3) (2012) (1)
- Second Cancers (SC) Affect the Clinical Outcome of Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Frontline FCR Therapy (2013) (1)
- Correlative patterns of neutrophil and platelet counts during very early remission of acute myeloblastic leukemia. (1987) (1)
- Comparison of Small Lymphocytic Lymphoma with Chronic Lymphocytic Leukemia The M.D Anderson Cancer Center Experience. (2005) (1)
- Targeted Therapy in Chronic Lymphocytic Leukemia (2008) (1)
- Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior. (2005) (1)
- Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells (2019) (1)
- Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro-Survival Responses in CLL Cells. (2008) (1)
- Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL (2010) (1)
- Single agent liposomal-encapsulated (Lipo) all-trans retinoic acid (ATRA) can cure patients with untreated acute promyelocytic leukemia (APL): An update and comparison with an ATRA+idarubicin induction regimen. (2004) (1)
- Hairy-cell leukemia: Successful treatment with interferon alpha (1985) (1)
- Population Pharmacokinetics of Alemtuzumab in Patients with Hematologic Malignancies. (2005) (1)
- heavy chain CDR3 expressed by chronic lymphocytic leukemia B cells is predicated on the Nonstochastic pairing of immunoglobulin heavy and light chains (2013) (1)
- Polyamines increase in human peripheral blood and bone marrow mononuclear cells following administration of methylglyoxal bis(guanylhydrazone). (1988) (1)
- Rituximab for chronic lymhocytic leukemia in treatment-naïve and Treatment-experienced patients (2012) (1)
- Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors. (2008) (1)
- Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab (2013) (1)
- Clinical Significance of Free Circulating CD4 and CD8 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. (2006) (1)
- Abstract 1248: Ibrutinib inhibits platelet aggregation through inhibition of mitochondrial respiratory chain function and suppression of Syk activation (2016) (1)
- Effect of a Co-Stimulatory Endodomain on the Performance of T Cells Expressing a Chimeric Antigen Receptor Directed at CD19 in Patients With Relapsed/Refractory B-Cell Malignancies (2011) (1)
- myelodysplastic syndrome and chronic myelomonocytic leukemia Topotecan, a topoisomerase I inhibitor, is active in the treatment of (2011) (1)
- IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL) (2015) (0)
- Clinical Significance of Free Circulating CD3 and CD5 in Patients with Chronic Lymphocytic Leukemia. (2006) (0)
- Randomized Phase II Study of Fludarabine1 Cytosine Arabinoside1 Idarubicin 6 All-Trans Retinoic Acid 6 Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome (1999) (0)
- Determining circulating therapeutic antibodies, antigens and antigen-antibody complexes with ELISA tests (2002) (0)
- Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR) (2017) (0)
- CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cellular Vascular Endothelial Growth Factor Is a Predictor of Outcome in Patients With Acute Myeloid Leukemia (2016) (0)
- OP68 Gene therapy for patients with CLL (2007) (0)
- MicroRNA Gene Transcription is Regulated by STAT3 in Chronic Lymphocytic Leukemia (CLL) Cells (2014) (0)
- CD20 Antigen Expression Is Increased in Trisomy 12 CLL as Compared to Other Cytogenetic Subtypes. (2006) (0)
- Prognostic determinants in patients (PTS) with Philadelphia chromosome-negative (Ph-Ve) benign phase chronic myelogenous leukemia (CML) (1985) (0)
- Resul ts of Treatment With Hyper-CVAD , a Dose-Intens ive Regimen , in Adul t Acute Lymphocyt ic Leukemia (2000) (0)
- Normalization of B2-microglobulin During the First Year of Treatment is Predictive for Prolonged Progression-free and Overall Survival in CLL Treated with FCR or Ibrutinib-based Regimens (2015) (0)
- Natural History and Terminal Events (2003) (0)
- Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia (2011) (0)
- Formulary decision making in a specialty hospital: effective management of potent and costly drug therapies. (1990) (0)
- Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia. (2007) (0)
- It is recommended that you download this PDF to your computer for furture reference. It spells out how CLL is treated clinically. (2008) (0)
- Cellular Metabolism and T-ALL Specificity of Arabinosylguanine: a Review (1998) (0)
- Should auer rods be used in the classification of myelodysplastic syndromes (MDS) (1994) (0)
- Hematology – Leading the Way (2017) (0)
- Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases (2007) (0)
- Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL. (2005) (0)
- Chronic lymphocytic leukaemia - a new revolution in treatment strategies? (2009) (0)
- Proceedings of the Annual Meeting of the Society of Hematologic Oncology, 2014 (2015) (0)
- Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab (2021) (0)
- Characteristics and Prognosis of Patients (pts) with Acute Megakaryocytic Leukemia (AMegL) Treated at M.D. Anderson Cancer Center Since 1987. (2004) (0)
- The proceedings of the initial meeting of the Society of Hematologic Oncology 2013. (2014) (0)
- Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing (2019) (0)
- Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience (2012) (0)
- Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C. (1986) (0)
- Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. (2008) (0)
- Abstract 4769:Ex-vivoandin-vitrocombination strategies with ibrutinib in chronic lymphocytic leukemia (2014) (0)
- The Natural History and Treatment Outcome of De-Novo Chromosome 17p Deletion CLL: A Single Institution Experience with 48 Patients. (2007) (0)
- **107 Monitoring of Innate Cellular Immune Responses in Chronic Lymphocytic Leukemia (CLL)-A Pilot Study (2011) (0)
- lymphocytic leukemia and is of prognostic significance Circulating CD20 is detectable in the plasma of patients with chronic (2013) (0)
- Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs (2010) (0)
- OSW-1: A novel anticancer agent with potent anticancer activity and unique mechanism of action. (2004) (0)
- Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia. (2004) (0)
- Nucleoside Analogs in Cancer Therapy (2021) (0)
- Abstract 4674: Restoration of Smac-mediated apoptosis in chronic lymphocytic leukemia (2012) (0)
- leukemogenic selection high-risk disease and reflects antigen-driven, post-germinal-center Use of IGHV3-21 in chronic lymphocytic leukemia is associated with (2013) (0)
- 4.27 Genomic Variability Predicts Time-to-Treatment in Previously Untreated CLL Patients (2011) (0)
- Results o f T reatment W ith H yper-CVAD, a D ose-Intensive Regimen, i n A dult A cute L ymphocytic L eukemia (2000) (0)
- Advances in the Management of Lymphoma (2002) (0)
- Patterns of Failure in Salvage Therapy for Acute Myelogenous Leukemia (1992) (0)
- Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes. (2004) (0)
- Lenalidomide Induced Graft Versus Leukemia in a Cll Patient Who Relapsed After Allogeneic Stem Cell Transplantion (2016) (0)
- Immunobiology and Immunophenotype of CLL cells (2003) (0)
- Phase I-II Study of Fludarabine, Cytarabine and Oxaliplatin In Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (2011) (0)
- Atlas do cancro em Portugal, 1980–82 (2004) (0)
- Ibrutinib for Chronic Lymphocytic Leukemia. (2016) (0)
- Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia (2016) (0)
- Sisomicin alone and in combination for infections in cancer patients (1979) (0)
- Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome. (2008) (0)
- Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. (2008) (0)
- PS1139 P300 INDUCES STAT3 ACETYLATION AND PROVIDES CLL CELLS WITH SURVIVAL ADVANTAGE (2019) (0)
- Randomized Phase II Study of Fludarabine 1 Cytosine Arabinoside 1 Idarubicin 6 All-Trans Retinoic Acid 6 Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome (1999) (0)
- **101 CCL3 (MIP-1 α) Plasma Levels and the Risk for Disease Progression in Chronic Lymphocytic Leukemia (CLL) (2011) (0)
- Right running head: ACTIVATION OF EXECUTIONER PROCASPASES IN CLL Journal section designation: LYMPHOID NEOPLASIA Title: Expression of executioner procaspases and their activation by a procaspase activating compound in chronic lymphocytic leukemia cells (2014) (0)
- High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. (2007) (0)
- Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells (2016) (0)
- Chronic lymphocytic leukemia chemotherapy: two decades of progress (2012) (0)
- PCN5 TREATMENT EFFECT OF RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE (R-FC) VERSUS FC IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN AN OBSERVATIONAL SETTING: AN INVESTIGATION OF PROGNOSTIC FACTORS AND LIFETIME HEALTH OUTCOMES (2008) (0)
- The current World Health Organization ( WHO ) classification of hematopoietic malignancies defines several types of mature T-cell leukemia including T-cell prolymphocytic leukemia (2004) (0)
- A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154. (2007) (0)
- 3.19 Disease Characteristics and Response to First Therapy in African American Patients with CLL: the M.D. Anderson Cancer Center Experience (2011) (0)
- Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib (2018) (0)
- Establishment of an In Vitro Study Model (0)
- Assessment of Immunoglobulin Heavy Chain Variable Region (IGHV) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD) (2021) (0)
- A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies (2022) (0)
- Plasma Circulating Caspase-3 Index as a Biomarker in Patients with Chronic Lymphocytic Leukemia. (2009) (0)
- Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. (2007) (0)
- Poster: CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells (2021) (0)
- Clinical Relevance of Soluble HLA-I as Compared to b2-MicroglobulinLevels in Non-Hodgkin’s Lymphoma and Hodgkin’s Disease. (2004) (0)
- challenged CLL lymphocytes by chlorinated ATP Cell death of bioenergetically compromised and transcriptionally (2013) (0)
- Interleukin-1 Receptor Antagonist and Interleukin-1 beta: Different Roles in Patients with Chronic Lymphocytic Leukemia. (2006) (0)
- To treat or not to treat (2012) (0)
- 慢性リンパ性白血病細胞においてCyclophosphamide活性体により誘導されたDNA障害修復のF-ara-Aによる阻害 (2002) (0)
- Abstract 1023: Duration of signaling through IgM and IgD receptors differentially influences cell survival and BCL6-regulated CCL3/4 chemokine production in Chronic Lymphocytic Leukemia (CLL) (2015) (0)
- Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia. (2005) (0)
- Predictors of survival in patients with transformed chronic lymphocytic leukemia (TC). (2013) (0)
- Acute leukaemia in adults: 1977 (1977) (0)
- Signal Transducer and Activator of Transcription (STAT)-3 Induces Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Receptor-α Expression in Chronic Lymphocytic Leukemia (CLL) Cells, (2011) (0)
- Phase I C linical a nd P harmacology S tudy o f C lofarabine i n Patients W ith S olid a nd H ematologic C ancers (2003) (0)
- New aspects of the treatment of chronic lymphocytic leukemia (2006) (0)
- 103 Gain of Chromosome 2p25.3 Involving the ACP1 Gene is Frequent in Chronic Lymphocytic Leukemia (2011) (0)
- Clinical Trials with Nucleoside Analogs in Other Hematologic Malignancies (2021) (0)
- Clinical Relevance of Circulating Poly-Ubiquitin as a Prognostic Indicator in Chronic Lymphocytic Leukemia. (2009) (0)
- Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients (2019) (0)
- Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). (2009) (0)
- Lenalidomide: an emerging option in chronic lymphocytic leukemia (2009) (0)
- 2.54 Targeting Refractory CLL Lacking ATM Function with Sapacitabine-Containing Therapy (2011) (0)
- Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype. (2007) (0)
- Growth dynamics in naturally progressing chronic lymphocytic leukaemia (2019) (0)
- Comparison of BM stromal cells from CLL patients to normal individuals (2015) (0)
- Post-remission chemotherapy for acute myeloid leukemia. (1995) (0)
- Ofatumumab (2018) (0)
- Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (2008) (0)
- Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p). (2013) (0)
- Biochemical Basis for Combination Chemotherapy (1992) (0)
- Clinical Trials of the Purine Analogs in Chronic Lymphocytic Leukemia (2021) (0)
- 249 ORAL Specific activation of microRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic response in chronic lymphocytic leukemia (2008) (0)
- Treatment o f P hiladelphia C hromosome-Posit ive E arly Chronic P hase C hronic M yelogenous L eukemia With D aily D oses o f I nterferon A lpha and L ow-Dose C ytarabine (1999) (0)
- Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality. (2012) (0)
- PCN70 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE REGIMEN—AN ECONOMIC EVALUATION BASED ON OBSERVATIONAL DATA (2008) (0)
- receiving alemtuzumab-based therapy Valganciclovir prevents cytomegalovirus reactivation in patients (2013) (0)
- Generation Of CLL-Specific CTL Effectors From Partially HLA-Matched Umbilical Cord Blood Grafts Using CD154-Transduced CLL Cell S As APCs (2009) (0)
- Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. (2006) (0)
- Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL (2015) (0)
- 4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia. (2005) (0)
- Long-Term Follow-Up of Patients with T-Large Granular Lymphocyte Leukemia (T-LGL); Experience in a Single Institution. (2005) (0)
- The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway. (2009) (0)
- Chromosome 17 Abnormalities Are Associated with Worse Overall and Relapse Free Survival in Patients with Acute Myelogenous Leukemia and Poor-Risk Cytogenetics. (2008) (0)
- Intrinsic oxidative stress and aberrations in mitochondrial DNA and mitochondrial mass in primary leukemia cells from CLL patients (2004) (0)
- Identification of B cell receptor antigens in the chronic lymphocytic leukemia microenvironment. (2015) (0)
- Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia (2020) (0)
- chronic lymphocytic leukemia Transient down-modulation of CD20 by rituximab in patients with (2013) (0)
- Glutathione plays an important role in tumor microenvironment-mediated drug resistance in chronic lymphocytic leukemia (2008) (0)
- chronic lymphocytic leukemia Perspectives on the use of new diagnostic tools in the treatment of (2013) (0)
- P300 Acetylates STAT3 and Increases Its Constitutive Transcriptional Activity in CLL Cells (2015) (0)
- Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance (2008) (0)
- Signal Transducer and Activator of Transcription (STAT)-3 Induces the Expression of Microrna-155 in Chronic Lymphocytic Leukemia (CLL) Cells. (2012) (0)
- Human cDNA expression arrays in normal and malignant monocytes (2000) (0)
- Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients. (2006) (0)
- Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib (2020) (0)
- Signal transducer and activator of transcription (STAT)-3 is a double edged sword in CLL cells (2015) (0)
- Prognostic factors in chronic myelomonocytic leukemia : a retrospective single institution analysis of 228 patients (1999) (0)
- Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene. (2019) (0)
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter’s Syndrome (2014) (0)
- Intertriginous infections in adults receiving antileukemia chemotherapy. (1989) (0)
- Targeting DNA repair in chronic lymphocytic leukemia cells with the DNA chain terminator, GS-9219 (2008) (0)
- Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells (2013) (0)
- Histone deacetylase inhibitors activate p73 to target chronic lymphocytic leukemia (2007) (0)
- Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies (2016) (0)
- Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia (2022) (0)
- Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia (2013) (0)
- Richter's syndrome: A report on response, survival, failure-free survival, and prognostic factors (2006) (0)
- Modulation of 9-/?-r>Arabinofuranosyladenme S'-Triphosphate and Deoxyadenosine Triphosphate in Leukemic Cells by 2'-Deoxycoformycin during Therapy with 9-ß-o-Arabinofuranosyladenine1 (2006) (0)
- ZAP70 Expression by Immunohistochemistry Correlates with IgVH Mutation Status in Chronic Lymphocytic Leukemia and Predicts Time to Progression, but Survival Is Decreased in p53-Positive CLL, Regardless of ZAP70 Expression. (2007) (0)
- Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells (2019) (0)
- Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneity and Resistance in Acute Leukemia (1992) (0)
- STAT3 Is Constitutively Phosphorylated on Serine 727 Residues, Activates Transcription, and Plays a Major Role in the Pathogenesis of B-Cell Chronic Lymphocytic Leukemia. (2008) (0)
- Clinical Significance of del11q FISH% in Patients With Chronic Lymphocytic Leukemia (CLL) – Can it Impact Prognostication in the Routine Clinical Practice? – Comprehensive Analysis From MD Anderson Cancer Center (2014) (0)
- Biologic and treatment determinants in curability of acute myelogenous leukemia (AML) (1986) (0)
- Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia. (2005) (0)
- CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment (2016) (0)
- Designing an effective products liability compliance program (2008) (0)
- Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications. (2007) (0)
- Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome. (2005) (0)
- 4 Targeted Therapy in Chronic Lymphocytic Leukemia (0)
- malignant B cells and overcome fludarabine resistance in CLL Targeting endoplasmic reticulum protein transport: a novel strategy to kill (2013) (0)
- T-cell prolymphocytic leukemia: 17-year experience at a single institution (2004) (0)
- chronic lymphoid leukemia Prognostic value of proliferating cell nuclear antigen expression in (2011) (0)
- Other cancers in long-term survivor patients with chronic lymphocytic leukemia (2015) (0)
- Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). (2018) (0)
- Abstract 4328: Marrow stromal cells promote mitochondrial energy metabolism in primary CLL cells without impacting cellular proliferation (2014) (0)
- Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy (2021) (0)
- Abstract 408: ATM function and mutation in CLL 11q deletion samples (2016) (0)
- Importin-β1 and Nucleus Transporter Chromosome Region Maintenance 1 (CRM1) Constitute the Nucleocytoplasmic Transport System of STAT3 in Blood-Derived CLL Cells. (2008) (0)
- Marrow proliferative activity in adult leukemia during remission induction therapy (1982) (0)
- Rituximab Improves Efficacy of Chemotherapy for Follicular Lymphomas (2002) (0)
- STAT3-Activated GM-CSFRα Shuttles To The Nucleus and Protects CLL Cells From Apoptosis (2013) (0)
- Azacytidine and Vorinostat in Patients with Chronic Lymphocytic Leukemia (CLL) Diagnosed with Therapy-Related Myelodysplastic Syndromes/Acute Myeloid Leukemia (t-MDS/AML) (2014) (0)
- Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. (2023) (0)
- Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center (2011) (0)
- Quantitation of BCR-ABL mRNA is emerging as the standard of care to monitor the status of chronic myeloid leukemia (2007) (0)
- Constitutively Serine Phosphorylated STAT3 Provides Chronic Lymphocytic Leukemia (CLL) Cells with Survival Advantage and Promotes Their Proliferation. (2007) (0)
- Analysis of human leukemias using extensive immunophenotypes from an antibody microarray (2006) (0)
- syndromes Angiogenesis in acute and chronic leukemias and myelodysplastic (2013) (0)
- Plasma Pharmacology of Fludarabine and Cellular Bioavailability of Fludarabine Triphosphate (1992) (0)
- Abstract 2658: Stromal microenvironment modulates mitochondrial metabolism in chronic lymphocytic leukemia cells and is abrogated by PI3K δ and γ inhibition (2015) (0)
- lymphocytic leukemia CD38 expression as an important prognostic factor in B-cell chronic (2013) (0)
- Characteristics, Response to Therapy and Outcome of African American Patients With Chronic Lymphocytic Leukemia (2013) (0)
- a redox-mediated mechanism Effective elimination of fludarabine-resistant CLL cells by PEITC through (2013) (0)
- Chronic Lymphocytic Leukemic Lymphocytes Proteasome Inhibitors Induce Apoptosis in Glucocorticoid-Resistant (2010) (0)
- Nelarabine (2021) (0)
- A Previously Unknown Pro-apoptotic Effect of STAT3 in CLL Cells of High Count CLL (2014) (0)
- Clinical Consequences of Defective B- and T-Cell Functions (2003) (0)
- Other Cancers in Patients With Chronic Lymphocytic Leukemia Requiring Therapy: Association With Prognostic Factors and Impact on Survival (2012) (0)
- Cardiovascular Adverse Events Associated with Ibrutinib in Chronic Lymphocytic Leukemia Patients (2015) (0)
- Use of Ubiquitin-Proteasome System Profiling for Differentiating Between Various Leukemic Processes. (2009) (0)
- Ibrutinib vs Clorambucilo-Burger-2015-e-pub (2016) (0)
- Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage (2018) (0)
- Prognostic significance of serum beta-2 microglobulin in myelodisplastic syndromes (2000) (0)
- Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome (2014) (0)
- Outcome of First Salvage Therapy in Patients With Chronic Lymphocytic Leukemia Relapsing After First-line Fludarabine, Cyclophosphamide, and Rituximab (2009) (0)
- Cytogenetic Findings and Pattern of Clonal Evolution Determine Survival in Patients with Primary or Secondary Myelofibrosis (2007) (0)
- Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes (2012) (0)
- lymphocytic leukemia splice variants is a distinctive feature of poor-prognosis chronic High expression of activation-induced cytidine deaminase ( AID ) and (2003) (0)
- 219: STAT3 induces proapoptotic signals in chronic lymphocytic leukemia (CLL) cells (2013) (0)
- Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL) (2016) (0)
- Abstract 120: Epigenetic silencing of miR-17 and miR-20a in chronic lymphocytic leukemia (2012) (0)
- Future Role of Purine Analogues in Oncology (1997) (0)
- CLL Cells with 13q- Are Characterized By High BCL2 Levels and CLL Cells with Trisomy-12 By Increased Activation of STAT3 and NF-κB (2018) (0)
- Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL (2019) (0)
- Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia. (2005) (0)
- The Use of Fludarabine in Chronic Lymphocytic Leukemia and Malignant Lymphomas (1996) (0)
- Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia (2011) (0)
- Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year (2022) (0)
- STAT3-Driven, Aberrantly Expressed Lipoprotein Lipase Mediates Free Fatty Acid Metabolism in Chronic Lymphocytic Leukemia Cells (2014) (0)
- Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response (2018) (0)
- CLL and Fat Cells Utilize Similar Metabolic Pathways (2017) (0)
- Migratory Pruritus (1960) (0)
- Retrospect of hematological malignancies 2012. (2013) (0)
- Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3. (2009) (0)
- Suppl-Resonate-2-Burger-2015 (2016) (0)
- in thronic Long-Term Results of CAP Therapy Lymphocytic Leukemia (1990) (0)
- Pretreatment prognostic factors associated with outcomes for first-line FCR-based treatments in previously untreated CLL. (2012) (0)
- CELLULAR PHARMACOKINETICS OF araCTP DURING THERAPY OF REFRACTORY ACUTE LEUKEMIA WITH araC: EFFECT OF m-AMSA: 163 (1985) (0)
- T-cell prolymphocytic leukemia: 17-year experience at a single institution. (2004) (0)
- identifies susceptibility loci for chronic lymphocytic leukemia A high-density SNP genome-wide linkage search of 206 families (2013) (0)
- Program Genealogies: A History of Leukemia Research at MD Anderson Cancer Center (1965-Present) (2017) (0)
- Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors (2017) (0)
- Introduction to leukemia long‐term survival (1997) (0)
- Stimulation of the B-Cell Receptor (BCR) Induces Tyrosine Phosphorylation of STAT3 via NF-κB Dependent Mechanism (2016) (0)
- Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy. (2005) (0)
- vivo lymphocytic leukemia cell survival and tissue homing in vitro and in The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic (2012) (0)
- Identification of novel B cell receptor antigens in chronic lymphocytic leukemia. (2016) (0)
- Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide (2015) (0)
- Abstract 4408: Metabolic alterations induced by ibrutinib in CLL cells as a basis for drug combinations to enhance ibrutinib therapeutic activity (2017) (0)
- CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells (2021) (0)
- Topotecan a nd C ytarabine I s a n A ctive C ombination Regimen i n M yelodysplastic S yndromes a nd C hronic Myelomonocytic L eukemia (1999) (0)
- 5.39 Feasibility Analysis of Non-myeloablative Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia and 17p Deletion (2011) (0)
- 2.53 HDAC-Mediated Silencing of miR-17 and miR-20a in Chronic Lymphocytic Leukemia (2011) (0)
- Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents (2014) (0)
- Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL (2012) (0)
- Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience. (2005) (0)
- Leukemia research, 2008. (2009) (0)
- High Levels of Soluble HLA-I in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: Relevance to Clinical Behavior and b2M Levels. (2004) (0)
- Analysis of PllO * " " " " * ' Tyrosine Protein Kinase Activity in Various Subtypes of Philadelphia Chromosome-positive Cells from Chronic Myelogenous Leukemia Patients 1 (2006) (0)
- Abstract 2697: A novel therapeutic strategy to effectively kill CLL cells in stromal microenvironment by targeting lipid metabolism (2014) (0)
- Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia. (2007) (0)
- Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL). (2012) (0)
- Randomized study of carbenicillin plus aminoglycoside antibiotics (AA) by continuous infusion in neutropenic patients (1976) (0)
- Signal Transducer and Activator Of Transcription 3 Activates and Deregulates Micro RNA Expression In Chronic Lymphocytic Leukemia Cells (2013) (0)
- Modulation of Ara-C Metabolism to Improve AML Response (1998) (0)
- A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin in Patients with Relapsed or Refractory Acute Myeloid Leukemia (2015) (0)
- Coexistence of Mutated and Unmutated IgVH Forms in Patients with Chronic Lymphocytic Leukemia. (2005) (0)
- Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML. (2005) (0)
- Approach to frontline therapy in elderly chronic lymphocytic leukemia patients (2013) (0)
- New approaches to the treatment of chronic myelogenous leukemia. (1985) (0)
- P300 Induces STAT3 Acetylation and Provides CLL Cells with Survival Advantage (2019) (0)
- relapsed and refractory chronic lymphocytic leukemia Lenalidomide induces complete and partial remissions in patients with (2013) (0)
- Symptom Assessment in Patients with Chronic Lymphocytic Leukemia: Validation and Application of the M.D. Anderson Symptom Inventory. (2005) (0)
- Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML). (2006) (0)
- ZAP-70 Status Does Not Predict Outcome after Nonmyeloablative Allogeneic Stem-Cell Transplantation (NST) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) That Fails To Respond to Conventional Chemoimmunotherapy. (2006) (0)
- The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience. (2007) (0)
- Therapy of acute myelogeneous leukemia. (1978) (0)
- Poster: CLL-162 PTX3 is Constitutively Active in CLL Cells (2022) (0)
- Abstract 1191: Role of histone deacetylases in silencing functionally relevant microRNAs in CLL (2011) (0)
- The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype: CLL‐085 (2018) (0)
- STAT3-induced GM-CSFRα Protects Chronic Lymphocytic Leukemia (CLL) Cells From Apoptosis (2014) (0)
- Hyper-CVAD P rogram i n B urkitt's-Type A dult A cute Lymphoblastic L eukemia (1999) (0)
- Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. (2008) (0)
- advanced leukemia Clofarabine, a novel nucleoside analog, is active in pediatric patients with (2013) (0)
- Early Treatment with Ofatumumab in Patients with High-Risk CLL (2022) (0)
- Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12 (2012) (0)
- Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL, (2011) (0)
- Circulating CD52 and CD20 Levels Predict for Progression and Survival in Patients with CLL Treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR). (2006) (0)
- Modulation of Ara-C Metabolism by Fludarabine: Therapy for Acute Myelogenous Leukemia (1994) (0)
- The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies (2010) (0)
- Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs). (2019) (0)
- The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set (2012) (0)
- Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia. (1984) (0)
- Prognostic factors in response to anthracyclines. (1981) (0)
- 52 Constitutive Serine Phosphorylation of STAT3 Induces Proliferation of Chronic Lymphocytic Leukemia Cells (2007) (0)
- Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors (1989) (0)
- Abstract 1541: Role of GSH in mediating stromal-leukemia interaction and promoting cell survival and drug resistance in chronic lymphocytic leukemia (2010) (0)
- Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL). (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael J Keating?
Michael J Keating is affiliated with the following schools:
